Mode
Text Size
Log in / Sign up

Exoskeleton-assisted robotic therapy improves upper limb motor scores versus conventional rehabilitation in poststroke inpatientsRobotic Therapy Helps Stroke Patients Regain Arm Function Faster

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider exoskeleton-assisted robotic therapy for early poststroke upper limb recovery in inpatients with moderate-to-severe impairment.

This multicenter, single-blind randomized controlled trial enrolled 94 inpatients with moderate-to-severe upper limb impairment less than three months poststroke. The study took place across 8 stroke neurorehabilitation units. Participants were randomized to receive either 25 sessions of exoskeleton-assisted robotic-assisted therapy delivered five times per week for five weeks or conventional rehabilitation as the control group. A 6-month telephone follow-up was conducted at T2.

The primary outcome measured change in the Fugl-Meyer Assessment for Upper Limb motor section from baseline to treatment end. The robotic group showed significantly greater improvement than the control group with a median between-group difference of 22 points. This difference had a p-value less than 0.001. Regarding the minimal clinically important difference of 10 points or more on the Fugl-Meyer Assessment, 68.4% of the robotic group achieved this versus 31.8% in the control group. The odds ratio was 4.64 with a 95% confidence interval of 1.83 to 11.8 and a p-value less than 0.001.

Secondary outcomes including body function, activity, participation, and spasticity were assessed. All secondary outcomes improved significantly in both groups with no significant differences between groups. Spasticity showed no significant change. Safety data regarding adverse events or serious adverse events were not reported. Discontinuations occurred in 12% of participants. Further research should evaluate long-term effects and optimize protocols based on patient characteristics.

Exoskeleton-assisted robotic-assisted therapy offers significant clinical benefits in early poststroke upper limb recovery. The study design and population support cautious optimism for early intervention in this specific cohort.

This study looked at how well robotic therapy helps people recover arm movement after a stroke. Researchers tested 94 inpatients with moderate-to-severe upper limb impairment who were less than three months post-stroke. The participants were treated at eight stroke neurorehabilitation units.

The intervention group received 25 sessions of exoskeleton-assisted robotic-assisted therapy, five times a week for five weeks. The control group received conventional rehabilitation. The primary goal was to measure changes in motor function using the Fugl-Meyer Assessment for Upper Limb.

Results showed that the robotic group had significantly greater improvement than the control group. The median difference between groups was 22 points, with a p-value less than 0.001. Additionally, 68.4% of the robotic group reached the minimal clinically important difference compared to 31.8% in the control group.

Secondary outcomes related to body function, activity, and participation improved significantly in both groups, but there were no significant differences between them. Spasticity did not change significantly in either group. Twelve percent of participants dropped out of the study. No adverse events were reported.

The researchers suggest that further research is needed to evaluate long-term effects and to optimize protocols based on patient characteristics. This trial indicates that exoskeleton-assisted therapy offers significant clinical benefits for early post-stroke upper limb recovery.

What this means for you:
Robotic arm therapy showed better motor recovery than standard rehab in early post-stroke patients.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up36.0 mo
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: Robot-assisted therapy (RAT) with exoskeletons is believed to enhance motor recovery in stroke survivors. RAT offers intensive, feedback-based, task-oriented training to improve function. This study evaluated exoskeleton-based RAT integrated into usual rehabilitation care for individuals in early subacute stroke. METHODS: This multicenter randomized controlled trial was conducted across 8 stroke neurorehabilitation units over a 3-year period (December 2020-March 2024). Inpatients with moderate-to-severe upper limb impairment postsubacute stroke (<3 months poststroke) were randomized (1:1) to 25 sessions (5/week for 5 weeks) of exoskeleton-assisted RAT (robotic group) or conventional rehabilitation (control group). Outcome assessors were blinded. The primary outcome was the change in the Fugl-Meyer Assessment for Upper Limb (motor section, 0-66) from baseline to treatment end. Secondary outcomes addressed body function, activity (capacity/performance), and participation. Clinical assessments were at baseline (T0), posttreatment (T1), and 6-month telephone follow-up (T2). Odds ratio for achieving a minimal clinically important difference (≥10 points) on the Fugl-Meyer Assessment for Upper Limb was calculated. RESULTS: A total of 109 individuals with subacute stroke were screened. Of these, 94 (35% women; mean age 62.5±13.5 years; mean onset 34±28 days) were eligible and randomized, and 82 completed the intervention (12% dropout). No significant differences were observed at baseline, despite the median Fugl-Meyer score being 16 in the robotic group and 10 in the control group. The robotic group showed significantly greater improvement in Fugl-Meyer Assessment for Upper Limb motor score than the control group, with a median between-group difference of 22 points (<0.001). Minimal clinically important difference was reached by 68.4% in the robotic group versus 31.8% in the control group (odds ratio, 4.64 [95% CI, 1.83-11.8]; <0.001). All secondary outcomes improved significantly in both groups with no significant differences between groups, except for spasticity, which showed no significant change. CONCLUSIONS: Exoskeleton-assisted RAT offers significant clinical benefits in early poststroke upper limb recovery, yielding higher minimal clinically important difference rates on impairment outcomes but not on specific functional measures compared with conventional therapy. Further research should evaluate long-term effects and optimize protocols based on patient characteristics. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04697368.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.